News

Drug companies had incentives to participate in the deals to stave off the threat of U.S. tariffs on their products.

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio value into shareholder returns. Net asset value per share increased 3.2% during the half year to 114p

Pfizer is taking aim at an unusual target in its quest to get paid for millions of unwanted Covid-19 vaccines: air-traffic controllers. The drug giant has pursued European governments seeking to enforce pandemic-era contracts to buy billions of dollars’ worth of vaccines that haven’t yet been made and are no longer needed. In April, it won a yearslong legal fight to hold Poland and Romania to deals for more than 90 million shots.

The purchase adds an established hypertension brand to the company's cardiovascular range.

David Ellison needed more legal muscle. After Paramount suffered a bruising July hearing in its fight with a coalition of state attorneys general trying to block its $81 billion acquisition of Warner Bros. Discovery Ellison picked up the phone and called a lawyer used to hearing from CEOs in a jam: Beth Wilkinson. Wilkinson has successfully defended the National Football League and pharmaceutical giant Pfizer as well as Supreme Court Justice Brett Kavanaugh against accusations of sexual assault in his confirmation hearings, making her a go-to trial lawyer in high-stakes cases.

Tech firms are courting Democrats and hiring advisers to prepare for potential investigations if Republicans lose control of the House.

By Andrew Silver SHANGHAI, Aug 24 (Reuters) - Weight-loss drugmakers, vying to tighten the belts of Chinese consumers, are promoting obesity awareness in metro stations, exercise studios and soccer

After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.

Moderna and Merck are surging today after the two companies said their experimental mRNA-based treatment succeeded in a late-stage study of high-risk melanoma patients. The SPDR S&P Biotech ETF (XBI) jumped nearly 5%, while the NYSE Arca Pharmaceutical Index climbed over 3%. A positive clinical-trial result typically moves the companies developing the drug—and perhaps their closest competitors—not the entire healthcare sector.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call

SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.

This problem has a solution, and Pfizer is implementing it.

Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.

The stock's 6.4% yield is attractive, but it comes with risk.

Volatility in the stock market and the Magnificent Seven dominate the headlines. Investors are repositioning toward more value-based funds.

Novavax secures key partnerships and raises 2026 outlook while advancing its adjuvant platform in infectious disease and oncology.

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s chief executive, Pascal Soriot. After plunging on a Financial Times report of merger discussions with Bristol-Myers Squibb shares of AstraZeneca recovered somewhat when Reuters reported there are no ongoing talks. After rebuffing Pfizer’s $120 billion takeover bid in 2014, he steadily transformed AstraZeneca into one of the drug industry’s top growth stories.

Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.

Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

Moby summary of Pfizer Inc.'s Q2 2026 earnings call

The quarter exposed where Pfizer's recovery is really coming from

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

Pfizer faces $17 billion patent cliff as investors brace for earnings